Review article · 2025 · Open access

Nirsevimab for preventing respiratory syncytial virus lower respiratory tract infections in infants: a systematic review and meta-analysis

Samira Soudani, Lorenzo Bertizzolo, Mehdi Ghemmouri, Mary Chappell, Rachael McCool, Katie Reddish, Paul Miller, Erin Barker, Harriet Fewster

Frontiers in Public Health, 13, 1641085 · Published 24 October 2025 · DOI 10.3389/fpubh.2025.1641085

Open PDFView at the publisherCite this paper

In brief

“Nirsevimab for preventing respiratory syncytial virus lower respiratory tract infections in infants: a systematic review and meta-analysis” is a 2025 review article by Samira Soudani and 8 co-authors, published in Frontiers in Public Health. OpenAlex counts 8 citations as of 18 November 2026, which puts it in the top 2% of works published in 2025 by citations. It is open access under a CC BY licence: the full text is free to read at Frontiers in Public Health.

Citations
8
Most cited in
2026 (8)
Field-weighted impact
0.93
References
33
Authors
9

Abstract

Background Respiratory syncytial virus (RSV) causes lower respiratory tract infections (LRTIs) in infants, leading to substantial morbidity and mortality. Nirsevimab, a long-lasting monoclonal antibody, has been demonstrated to reduce RSV-related outcomes in randomized controlled trials (RCTs) and real-world settings. The object was to review the existing real-world evidence (RWE) on the effectiveness of nirsevimab in preventing RSV-LRTIs. Methods Searches of six databases in addition to trial registries, HTA/regulatory agency webpages and conference abstracts were conducted in November 2024. Observational studies evaluating nirsevimab prophylaxis in infants during their first RSV season or high-risk infants in their second season were included. For outcomes evaluated by more than one study, feasibility assessment was conducted and, where appropriate, studies were combined in meta-analyses. Results Sixteen studies reporting effectiveness outcomes were included. The studies were conducted across four countries (Spain, Italy, US and France), and included 141,550 infants. Nirsevimab showed significant effectiveness for preventing RSV-LRTI hospitalization (reduction in risk from hazard ratios and odds ratios of 84.5%; 95% CI: 73.6%−90.9%; I 2 : 0 and 73.7%; 95% CI: 42.3%−88.0%; I 2 : 0%, respectively), intensive care unit (ICU) admission (85.9%; 95% CI: 13.2%−97.7%) and ventilatory support (87.1%; 95% CI: 70.2%−94.4%). Nirsevimab was also effective in preventing RSV-LRTI visits in primary care (75.8%; 95% CI: 40.4%−92.7%) and emergency departments (87.9%; 70.3%−95.1%). Conclusions Real-world evidence confirms the effectiveness of nirsevimab against RSV-LRTIs and underlines the public health impact of the intervention in preventing RSV-related health outcomes. There is no clear evidence that effectiveness differs for infants born in season (at birth immunization) compared with out of season groups, or that effectiveness varies in preterm infants compared to healthy term infants. Systematic review registration https://www.crd.york.ac.uk/PROSPERO/view/CRD42024591323 .

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Soudani, S., Bertizzolo, L., Ghemmouri, M., Chappell, M., McCool, R., Reddish, K., Miller, P., Barker, E., & Fewster, H. (2025). Nirsevimab for preventing respiratory syncytial virus lower respiratory tract infections in infants: a systematic review and meta-analysis. Frontiers in Public Health, 13, 1641085. https://doi.org/10.3389/fpubh.2025.1641085

MLA 9

Soudani, Samira, et al. “Nirsevimab for preventing respiratory syncytial virus lower respiratory tract infections in infants: a systematic review and meta-analysis.” Frontiers in Public Health, vol. 13, 2025, p. 1641085. https://doi.org/10.3389/fpubh.2025.1641085.

Chicago

Soudani, Samira, Lorenzo Bertizzolo, Mehdi Ghemmouri, Mary Chappell, Rachael McCool, Katie Reddish, Paul Miller, Erin Barker, and Harriet Fewster. 2025. “Nirsevimab for preventing respiratory syncytial virus lower respiratory tract infections in infants: a systematic review and meta-analysis.” Frontiers in Public Health 13: 1641085. https://doi.org/10.3389/fpubh.2025.1641085.

Harvard

Soudani, S. et al. (2025) ‘Nirsevimab for preventing respiratory syncytial virus lower respiratory tract infections in infants: a systematic review and meta-analysis’, Frontiers in Public Health, 13, p. 1641085. doi:10.3389/fpubh.2025.1641085.

IEEE

S. Soudani et al., “Nirsevimab for preventing respiratory syncytial virus lower respiratory tract infections in infants: a systematic review and meta-analysis,” Frontiers in Public Health, vol. 13, p. 1641085, 2025, doi: 10.3389/fpubh.2025.1641085.

BibTeX

@article{soudani2025nirsevimab,
  title     = {{Nirsevimab for preventing respiratory syncytial virus lower respiratory tract infections in infants: a systematic review and meta-analysis}},
  author    = {Soudani, Samira and Bertizzolo, Lorenzo and Ghemmouri, Mehdi and Chappell, Mary and McCool, Rachael and Reddish, Katie and Miller, Paul and Barker, Erin and Fewster, Harriet},
  journal   = {Frontiers in Public Health},
  year      = {2025},
  volume    = {13},
  pages     = {1641085},
  doi       = {10.3389/fpubh.2025.1641085},
  url       = {https://doi.org/10.3389/fpubh.2025.1641085}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Epidemiology › Respiratory viral infections research

  • nirsevimab
  • respiratory syncytial virus
  • lower respiratory tract infection
  • infants
  • prophylaxis
  • monoclonal antibodies
  • hospitalization prevention
  • intensive care unit admission

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Soudani, S., Bertizzolo, L., Ghemmouri, M., Chappell, M., McCool, R., Reddish, K., Miller, P., Barker, E., & Fewster, H. (2025). Nirsevimab for preventing respiratory syncytial virus lower respiratory tract infections in infants: a systematic review and meta-analysis. Frontiers in Public Health, 13, 1641085. https://doi.org/10.3389/fpubh.2025.1641085

How many times has this paper been cited?

8 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Frontiers in Public Health: sign in and open the PDF from this page.

Who wrote this paper?

Samira Soudani, Lorenzo Bertizzolo, Mehdi Ghemmouri, Mary Chappell, Rachael McCool, Katie Reddish, Paul Miller, Erin Barker, Harriet Fewster.

What is the DOI of this paper?

10.3389/fpubh.2025.1641085, permanently at https://doi.org/10.3389/fpubh.2025.1641085. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.